While Sandoz has emerged as the front-runner to get a generic version of GlaxoSmithKline’s respiratory blockbuster Advair to the US market, rival Hikma has not given up despite a major setback.

UK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for approval of its generic of GlaxoSmithKline’s blockbuster respiratory drug Advair. Hikma has been ...

Generics’ core operating profit fell 11 per cent due to higher royalties for Hikma’s authorised generic of sodium oxybate.

AMMAN — Hikma Pharmaceuticals PLC posted 'robust ... strengthened its market position as the seventh-largest supplier of ...

Hikma is a top three provider of generic sterile injectables by volume and a key supplier of non-injectable generic medicines in the US. In the Mena region, we are the second largest ...